35 Results for "

GPR55

" in MedChemExpress (MCE) Product Catalog:
Products (35)

35 Results for "GPR55" in MCE Product Catalog:

26
26 Publications Verification
Cat. No.: HY-15443
CAS No.: 183232-66-8
Purity:  99.09%
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10863
CAS No.: 94421-68-8
Purity:  ≥98.0%
Synonyms: AEA; Arachidonoyl ethanolamide
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-110125
CAS No.: 713121-80-3
Purity:  99.82%
Synonyms: CID 1261822
Target:  

GPR55

Research Areas:  

Neurological Disease

ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16697
CAS No.: 834903-43-4
Target:  

GPR55

Research Areas:  

Cancer

CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca 2+ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107541
CAS No.: 317321-41-8
Purity:  99.68%
Target:  

GPR55

Research Areas:  

Neurological Disease

O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107536
CAS No.: 1164500-72-4
Purity:  96.09%
Target:  

GPR35 CXCR

ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
loading...
    loading...
Cat. No.: HY-116637
CAS No.: 20601-85-8
Purity:  99.79%
Synonyms: Magnolignan
Tetrahydromagnolol (Magnolignan), the main metabolite of Magnolol, is a potent and selective cannabinoidCB2 receptor agonist (EC50 =170 nM) and GPR55 antagonist. The Ki of Tetrahydromagnolol for CB2 is 416 nM, 20-fold higher than for the CB1 receptor. Magnolol shows antifungal, anti-inflammatory and analgesic effects .
loading...
    loading...
Cat. No.: HY-156157
CAS No.: 3006105-55-8
Purity:  98.36%
Target:  

GPR55

Research Areas:  

Cancer

GPR55 agonist 4 (Compound 28) is a GPR55 agonist (EC50: 131 nM, and 1.41 nM for hGPR55 and rGPR55). GPR55 agonist 4 induces β-arrestin recruitment to human GPR55 .
loading...
    loading...
Cat. No.: HY-156107
CAS No.: 3006105-44-5
Purity:  99.17%
Target:  

GPR55

Research Areas:  

Cancer

GPR55 agonist 3 (Compound 26) is a GPR55 agonist (EC50: 0.239 nM, and 1.76 nM for hGPR55 and rGPR55). GPR55 agonist 3 induces β-arrestin recruitment to human GPR55 (EC50: 6.2 nM) .
loading...
    loading...
Cat. No.: HY-W020035
CAS No.: 796963-91-2
Target:  

GPR55

Research Areas:  

Neurological Disease

L-α-lysophosphatidylinositol Soy sodium is an endogenous ligand of GPR55. L-α-lysophosphatidylinositol Soy sodium is an endogenous lysophospholipid and endocannabinoid neurotransmitter that belongs to the class of lysophospholipids .
loading...
    loading...
Cat. No.: HY-122246
CAS No.: 460331-61-7
Target:  

GPR55 PKC ERK Arrestin

Research Areas:  

Metabolic Disease

ML192 is a selective ligand antagonist of GPR55. ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocation .
loading...
    loading...
Cat. No.: HY-111083
CAS No.: 931695-79-3
Purity:  99.65%
Synonyms: CID23612552
Target:  

GPR55 PERK PKC ERK p38 MAPK

Research Areas:  

Metabolic Disease Cancer

ML191 (CID23612552) is a GPR55 antagonist. ML191 inhibits ERK phosphorylation and PKC β II translocation downstream of GPR55 signaling. ML191 suppresses LPI-induced activation of ERK1/2 and p38 MAPK signaling, blocks the transcription of RANKL-induced osteoclastogenesis markers, and reduces the bone resorption activity of mature osteoclasts promoted by RANKL. ML191 can be used to investigate diseases associated with bone degradation caused by excessive osteoclast activation, such as osteoporosis and bone damage during the formation stage of bone metastases .
loading...
    loading...
Cat. No.: HY-116461
CAS No.: 794572-10-4
Purity:  99.57%
Synonyms: CID2440433
Target:  

GPR55

Research Areas:  

Neurological Disease

ML-184 (CID244033) is a selective GPR55 agonist with an EC50 of 250 nM, more than 100-fold selectivity for GPR55 over GPR35, CB1, and CB2. ML-184 induces ERK1/2 phosphorylation and PKCβII translocation to the plasma membrane via activation of GPR55. ML-184 (CID2440433) increases the proliferation of neural stem cells and promotes neuronal differentiation in vitro .
loading...
    loading...
Cat. No.: HY-162618
CAS No.: 885896-54-8
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

PSB-KK1445 is a potent and selective GPR18 agonist with EC50s of 45.4 nM and 124 nM for human and mouse GPR18, respectively. PSB-KK1445 displays >200-fold selectivity versus both CB receptor subtypes, GPR55, and GPR183 .
loading...
    loading...
Cat. No.: HY-150187
CAS No.: 1246430-04-5
Research Areas:  

Neurological Disease

20:4 Lyso PI acts as an activator of GPR55 and RhoA. 20:4 Lyso PI activates the GPR55-RhoA-ROCK pathway, thereby inducing morphological changes, cytoskeleton assembly, cell rounding and stress fiber formation. 20:4 Lyso PI can be used in research related to diseases such as those of the nervous system .
loading...
    loading...
Cat. No.: HY-10863S
CAS No.: 924894-98-4
Synonyms: AEA-d8
Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .
loading...
    loading...
Cat. No.: HY-125111
CAS No.: 1399049-81-0
Purity:  99.36%
PSB-SB-487 is a potent GPR55 antagonist and CB2 agonist with an IC50 value of 0.113 µM for GPR55, and a Ki value of 0.292 µM for human CB2. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer .
loading...
    loading...
Cat. No.: HY-RS05721
Research Areas:  

Others

GPR55 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR55 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS05722
Research Areas:  

Others

Gpr55 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpr55 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS05723
Research Areas:  

Others

Gpr55 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpr55 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...